Atossa TherapeuticsATOS +9.21%26 EV-to-EBIT is 0.17 as of Jul. 08, 2026, which is 66% below its 10-year median of 0.50. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 365 Biotechnology companies, Atossa Therapeutics ranks better than 91.23% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Atossa Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $13.58 Mil.
Atossa Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atossa Therapeutics EV-to-EBIT Related Terms
Atossa Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Atossa Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atossa Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atossa Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Atossa Therapeutics's EV-to-EBIT falls into.
Atossa Therapeutics's current Enterprise Value is $-6.88 Mil.
Atossa Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atossa Therapeutics (ATOS) has a EV-to-EBIT of 0.17 as of Jul. 08, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Atossa Therapeutics and its competitors. This is 66% below median its historical median of 0.50. According to the industry distribution chart, Atossa Therapeutics ranks #32 out of 365 companies in the Biotechnology industry, placing it in the top 8.8%.
Is Atossa Therapeutics' EV-to-EBIT too high?
Atossa Therapeutics' current EV-to-EBIT of 0.17 is 66% below median its 10-year median of 0.50. The Biotechnology industry median EV-to-EBIT is 14.69. Atossa Therapeutics' value of 0.17 is 98.8% below this industry median. Based on the distribution chart, Atossa Therapeutics ranks #32 out of 365 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' EV-to-EBIT compare to QNCX and ZIVO?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #32 out of 365 companies for EV-to-EBIT. This places Atossa Therapeutics in the top 9% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 14.69. Atossa Therapeutics' value of 0.17 is 98.8% below this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 14.69, Atossa Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.69, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atossa Therapeutics's current EV-to-EBIT of 0.17 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Atossa Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atossa Therapeutics's current EV-to-EBIT is 0.17, which is 66% below median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current EV-to-EBIT of 0.17. The current EV-to-EBIT is 0.17, which is 66% below median its 10-year median of 0.50 and 98.8% below the Biotechnology industry median of 14.69. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current EV-to-EBIT is 0.17 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score
Get the complete analysis for ATOS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATOS has been successfully added to your 
